James Quigley
Stock Analyst at Morgan Stanley
(0)
# 4804
Out of 5,356 analysts
29
Total ratings
66.67%
Success rate
-21.23%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
KYMR Kymera Therapeutics | Upgrades: Overweight | 49 79 | 47.62 | 65.9% | 6 | Jun 3, 2025 | |
SNY Sanofi | Initiates Coverage On: Neutral | 65 | 49.73 | 30.71% | 1 | Mar 21, 2025 | |
NVS Novartis | Downgrades: Neutral | 119 121 | 117.65 | 2.85% | 1 | Sep 5, 2024 | |
MOR MorphoSys | Downgrades: Equal-Weight | n/a | n/a | n/a | 6 | Jan 19, 2024 | |
GRFS Grifols | Maintains: Neutral | 10 11 | 8.71 | 20.55% | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 42 40 | 27.96 | 43.06% | 10 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 12 16 | 4 | 300% | 3 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 25 | n/a | n/a | 1 | Nov 20, 2017 |